Vivoryon Therapeutics N.V. (0R3M.L)
| Previous close | 2.4950 |
| Open | 2.5650 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4500 - 2.5650 |
| 52-week range | 0.5000 - 19.4000 |
| Volume | |
| Avg. volume | 3,012 |
| Market cap | 31.997M |
| Beta (5Y monthly) | 1.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6330 |
| Earnings date | 23 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease
Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease New data confirm beneficial treatment effect of varoglutamstat on kidney functionTreatment effect1 in diabetes subgroup2 of >8mL/min/1.73m2/year in estimated glomerular filtration rate (eGFR); reinforces previously reported treatment effect of 3.4mL/min/1.73m2/year (p<0.001) in the
- Globe Newswire
Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease
Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Halle (Saale) / Munich, Germany, July 9, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will host an R&D update conference call and webcast on Thursday, July 18,
GlobeNewswireVivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items on the agend
